1397. Gender Differences in Virologic Response after Antiretroviral Therapy in Treatment-naïve HIV-infected Individuals: Results from the 550 Clinic HIV Cohort Study.
Session: Poster Abstract Session: HIV: Antiretroviral Therapy
Friday, October 6, 2017
Room: Poster Hall CD
Posters
  • Gender ID WEEK 2017 FINAL.pdf (473.9 kB)
  • Background: Controversy still exists regarding gender differences in virologic response between treatment-na•ve HIV-infected individuals. The objective of this study was to evaluate gender difference in virologic and immunologic response to antiretroviral therapy in treatment-na•ve HIV-infected individuals.

    Methods: This was a retrospective, observational study of treatment-na•ve HIV-infected individuals managed at the 550 clinic who started antiretroviral therapy (ART) between January 1st, 2010 and December 31, 2015. Patients with available viral load and CD4 counts before and one year after initiating ART were included in this study. Virologic suppression was defined as < 48 HIV-1 RNA copies/mL, and mmunologic recovery was defined as a CD4 count increase of at least 150 cells/mm3. Dichotomous variables were reported in number and percentages and analyzed using Chi-squared tests and FisherÕs exact (whichever was appropriate). Continuous variables were reported as median and interquartile range (IQR) and analyzed using Wilcox rank sum tests. Multivariate analyses performed were logistic regressions with adjustment for other covariates. P value <0.05 was considered statistically significant. R version 3.3.2 was used for the statistical analysis.

    Results: A total of 70 women and 90 men were included in the study. Median age was 41 years (19) for women and 34 years (19) for men (p<0.001). Virologic suppression was documented in 76% of women and 64% of men (p 0.166). Immune recovery was documented in 60% of women and 68% of men (p 0.323). Multivariate analysis of virologic success is shown in figure 1 and immunologic recovery is shown in figure 2.

    Conclusion: In our study, gender was not found to be associated with differences in response to ART. As expected, drug abuse continues to be an independent variable associated with lack of virologic suppression. If one of the goals of treatment is to achieve a rapid immunologic response, our study may indicate that regimens containing protease inhibitors should be the ones selected.

    Andrea Reyes Vega, MD1, Alejandra Loban, MD2, Kavitha Srinivasan, MD2, Stephen Furmanek, MS MPH2, Connor English, BS2, Mary Bishop, RPH1, Cathy Spencer, PharmD1, Daniel Truelove, PharmD2, Julio Ramirez, MD1, Anupama Raghuram, MD2 and Paula Peyrani, MD1, (1)Division of Infectious Diseases, University of Louisville, Louisville, KY, (2)Infectious Diseases, University of Louisville, Louisville, KY

    Disclosures:

    A. Reyes Vega, None

    A. Loban, None

    K. Srinivasan, None

    S. Furmanek, None

    C. English, None

    M. Bishop, None

    C. Spencer, None

    D. Truelove, None

    J. Ramirez, None

    A. Raghuram, None

    P. Peyrani, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.